PROF. MUZAFFAR LATIF GILL
PATIENT EDUCATION BLOG
32nd Annual Conference of Pakistan Society of Gastroenterology held in PC Hotel Rawalpindi (7th March, 2016)
Read More
32nd Annual Conference of Pakistan Society of Gastroenterology held in PC Hotel Rawalpindi (6th March, 2016)
Read More
32nd Annual Conference of Pakistan Society of Gastroenterology held in PC Hotel Rawalpindi (5th March, 2016)
Read More
32nd Annual Conference of Pakistan Society of Gastroenterology held in PC Hotel Rawalpindi (4th March, 2016)
Read More
OUTCOMES OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN PATIENTS WITH CIRRHOSIS

SIDRA GILL, NOSHEEN YOUSUF, AMMARA NAWAZ, RABBEA NAZIR, MUZZAFFAR GILL Background: ERCP is commonly performed in cirrhotics, they are at increased risk of bleeding after ERCP, but the incidence and risk-factors in this population is not well described. The aim of this study was to examine the incidence of post-ERCP complications. Methods: We evaluated all […]

Read More
OUTCOMES OF SOF AND RIBA THERAPY FOR HEP C G3 PATIENTS WHO ARE RELAPSERS OF PEG INF AND RIBAVIRIN

SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN Background and Aims: Sofosbuvir + Ribavirin is gold standard for chronic HEP-C patients. We evaluated the safety and efficacy of sofosbuvir and ribavirin in chronic HEP-C G3 patients. Methods: We prospectively enrolled 150 patients with chronic HEP- […]

Read More
OUTCOMES OF SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION

SIDRA GILL NOSHEEN YOUSUF, AMMARA NAWAZ , RABBEA NAZIR, MUZZAFFAR GILL Background: Recurrent hepatitis occurs in the vast majority of HCV-positive recipients who are viremic at the time of Liver Transplantation (LT). We evaluated safety and efficacy of all oral antiviral therapy (Tx) with Sofosbuvir plus Ribavirin in a population of HCV G3-infected patients. Methods: […]

Read More
OUTCOMES OF SOF, RIBA AND PEG-INF THERAPY FOR THE TREATMENT OF CHRONIC HEP-C G3 TREATMENT NAIVE PATIENTS

SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN Background: Sovaldi, Ribavirin and PEG-Interferon is gold standard therapy for chronic HEP-C patients. It is recommended both for treatment naive and experienced patients. We evaluated the safety and efficacy of this combination in naïve chronic HEP-C G3 […]

Read More
Certificate of APASL, Awarded to Prof. Muzzaffar Gill for Moderating Conference.

Certificate of APASL, Awarded to Prof. Muzzaffar Gill for Moderating Conference.

Read More
Professor Gill’s team presented four research papers in Tokyo Japan.

Professor Gill's team has presented four research research papers In 25th Asian Pacific association for study of liver diseases (APASL) Which was held in Tokyo Japan from Feb 20-24 , 2016 On behalf of the 25th Asian Pacific Association for the Study of the Liver (APASL 2016) "Modern Hepatology", that will be held on February […]

Read More
Book Consultation
Leading Gastroenterologist & Hepatologist: Dedicated to your digestive health and liver wellness."

Working Hours

Monday: 
11am - 6pm
Tuesday: 
11am - 6pm
Wednesday: 
11am - 6pm
Thursday: 
11am - 6pm
Friday:
11am - 6pm
Saturday:
11am - 6pm

Copyright © 2024 Prof Muzaffar Latif Gill. All rights reserved. Powered By AKITS

Disclaimer: This website’s content is for educational purposes only and should not replace professional medical advice or treatment.
We are not liable for the accuracy, completeness, or timeliness of the information, nor for any actions taken based on it.

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram